Hangzhou Diagens Biotechnology Co., Ltd. (HKG:2526)

Market Cap	29.33B
Revenue (ttm)	182.97M +133.7%
Net Income	-74.71M
EPS	-0.93
Shares Out	88.88M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	269,300
Average Volume	185,431
Open	329.60
Previous Close	330.00
Day's Range	286.00 - 329.60
52-Week Range	178.00 - 345.00
Beta	n/a
RSI	57.86
Earnings Date	Jun 18, 2026

About HKG:2526

Hangzhou Diagens Biotechnology Co., Ltd., a medical devices company, develops medical imaging products and services. It operates through Medical Imaging Software and Medical Devices, Technology Licensing, Analysis and Consulting Services, and Others segments. The company’s products portfolio include AI AutoVision, a chromosome karyotype assisted diagnosis and analysis system that provides intelligent karyotyping analysis with applications across genetics and hematologic oncology; MetaSight automatic cell microscopic image scanning system, which...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2016
• Employees: 166
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2526

Financial Performance

In 2025, HKG:2526's revenue was 164.42 million, an increase of 133.72% compared to the previous year's 70.35 million. Losses were -67.14 million, 54.8% more than in 2024.

Financial numbers in CNY